1. Home
  2. ICCC vs EDAP Comparison

ICCC vs EDAP Comparison

Compare ICCC & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • EDAP
  • Stock Information
  • Founded
  • ICCC 1982
  • EDAP 1979
  • Country
  • ICCC United States
  • EDAP France
  • Employees
  • ICCC N/A
  • EDAP N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ICCC Health Care
  • EDAP Health Care
  • Exchange
  • ICCC Nasdaq
  • EDAP Nasdaq
  • Market Cap
  • ICCC 57.4M
  • EDAP 46.7M
  • IPO Year
  • ICCC 1987
  • EDAP 1997
  • Fundamental
  • Price
  • ICCC $6.61
  • EDAP $2.21
  • Analyst Decision
  • ICCC
  • EDAP Buy
  • Analyst Count
  • ICCC 0
  • EDAP 3
  • Target Price
  • ICCC N/A
  • EDAP $8.50
  • AVG Volume (30 Days)
  • ICCC 17.1K
  • EDAP 43.9K
  • Earning Date
  • ICCC 11-12-2025
  • EDAP 11-06-2025
  • Dividend Yield
  • ICCC N/A
  • EDAP N/A
  • EPS Growth
  • ICCC N/A
  • EDAP N/A
  • EPS
  • ICCC 0.20
  • EDAP N/A
  • Revenue
  • ICCC $28,274,756.00
  • EDAP $74,008,221.00
  • Revenue This Year
  • ICCC N/A
  • EDAP N/A
  • Revenue Next Year
  • ICCC N/A
  • EDAP N/A
  • P/E Ratio
  • ICCC $32.15
  • EDAP N/A
  • Revenue Growth
  • ICCC 21.75
  • EDAP 1.56
  • 52 Week Low
  • ICCC $3.38
  • EDAP $1.21
  • 52 Week High
  • ICCC $7.60
  • EDAP $3.08
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 58.43
  • EDAP 45.93
  • Support Level
  • ICCC $6.30
  • EDAP $2.25
  • Resistance Level
  • ICCC $6.99
  • EDAP $2.79
  • Average True Range (ATR)
  • ICCC 0.30
  • EDAP 0.21
  • MACD
  • ICCC 0.06
  • EDAP -0.07
  • Stochastic Oscillator
  • ICCC 69.06
  • EDAP 16.95

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: